What we say:
Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Pioglitazone (trade name: actos), a glucose lowering drug, promotes an insulin-sensitized state via up-regulation of its target gene Lin-28
[easy_payment currency=”USD”]
From Significance of the study to Public health relevance:
Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) diabetic disease results in a number of health complications, including diabetic cardiomyopathy (DCM), diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy; (3) one third of people with diabetes suffer from diabetic kidney disease (DKD); and one third of them will develop kidney failure; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.
From Research findings to Therapeutic opportunity:
Piogliotazone, an anti-hyperglycemic drug used in the treatment of T2DM, is one of the best selling antidiabetic drug in the US whose sales had exceeded $2.4 billion in 2008. This study provides mechanistic insight into how how Pioglitazone functions as an anti-hyperglycemic/cardioprotective agent.
Pioglitazone, by decreasing the expression of its target gene, it may (1) increase the expression of Lin-28, IGF1R, INSR, and IRS2; (2) enhance tissue repair; (3) promote regenerative capacity; (4) promote insulin sensitivity; (5) decrease myocardial infarct size; and (6) inhibit diabetic cardiomyopathy (fig 1).
Figure 1. Mechanistic insights into how Pioglitazone functions as an anti-hyperglycemic/cardioprotective agent. Pioglitazone, by increasing the expression of reprogramming protein Lin-28, IGFIR, INSR, and IRS2, it may promote insulin sensitivity and protect from diabetic cardiomyopathy.
Thus, pharmacological formulations encompassing “Pioglitazone or its analogues either alone or in combination with other drugs” may be used to treat TIIDM and diabetic cardiomyopathy.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Amount: $ 300#
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Pioglitazone promote insulin-sensitized state?
# Research cooperation
For purchase details, you may reach us at info@genomediscovery.org
References:
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan L, Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Pioglitazone (trade name: actos), a glucose lowering drug, promotes an insulin-sensitized state via up-regulation of its target gene Lin-28, 21/March/2017, 11.18 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org